• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

SR9009

CAS No. 1379686-30-2

SR9009 ( SR9009 | SR 9009 | SR-9009 | Stenabolic )

产品货号. M17268 CAS No. 1379686-30-2

SR9009 是一种 REV-ERB 激动剂,可增加 REV-ERBα/ERBβ 调节的基因的组成型抑制(IC50:670/800 nM)。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
2MG ¥316 有现货
5MG ¥568 有现货
10MG ¥800 有现货
25MG ¥1218 有现货
50MG ¥2251 有现货
500MG 获取报价 有现货
1G 获取报价 有现货
1 mL x 10 mM in DMSO ¥682 有现货

生物学信息

  • 产品名称
    SR9009
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    SR9009 是一种 REV-ERB 激动剂,可增加 REV-ERBα/ERBβ 调节的基因的组成型抑制(IC50:670/800 nM)。
  • 产品描述
    SR9009, a REV-ERB agonist, increases the constitutive repression of genes regulated by REV-ERBα/ERBβ (IC50: 670/800 nM). Through activation of REV-ERB, SR9009 can decrease circadian locomotor activity during the dark phase and alter the expression pattern of core clock genes in the hypothalami of mice.?The circadian pattern of expression of an array of metabolic genes in the liver, skeletal muscle, and adipose tissue was also altered in mice exposed to SR9009, resulting in increased energy expenditure.?In Diet-induced obese mice, SR9009 (100 mg/kg, i.p., b.i.d., for 30 days) could decrease fat mass and markedly improve dyslipidemia and hyperglycemia.(In Vitro):SR9009 dose-dependently increases the REV-ERB-dependent repressor activity assessed in HEK293 cells expressing a chimeric Gal4 DNA Binding Domain (DBD)-REV-ERB ligand binding domain (LBD)α or β and a Gal4-responsive luciferase reporter (SR9009: REV-ERBα IC50=670 nM, REV-ERBβ IC50=800 nM). SR9009 potently and efficaciously suppresses transcription in a cotransfection assay using full-length REV-ERBα along with a luciferase reporter driven by the Bmal1 promoter (IC50=710 nM). SR9009 suppresses the expression of BMAL1 mRNA in HepG2 cells in a REV-ERBα/β-dependent manner. Direct binding of the SR9009 to REV-ERBα is also confirmed using circular dichrosim analysis (Kd=800 nM). (In Vivo):While the stress of handling and twice-daily injections caused weight loss in vehicle-treated controls, weight loss of SR9009-treated animals is 60% greater. SR9009 (100 mg/kg ,i.p.) treated mice exhibit a more severe reduction in adiposity. Plasma non-esterified fatty acids (NEFA) are also reduced (23%) along with plasma glucose (19%) in the SR9009 treated animals. In the white adipose tissue (WAT) , SR9009 treatment results in a decrease in expression of genes encoding enzymes involved in triglyceride (TG) synthesis as is also observed in lean mice.
  • 体外实验
    ——
  • 体内实验
    ——
  • 同义词
    SR9009 | SR 9009 | SR-9009 | Stenabolic
  • 通路
    Metabolic Enzyme/Protease
  • 靶点
    Retinoid Receptor
  • 受体
    Rev-ErbBα| Rev-ErbBβ
  • 研究领域
    Others-Field
  • 适应症
    ——

化学信息

  • CAS Number
    1379686-30-2
  • 分子量
    437.94
  • 分子式
    C20H24ClN3O4S
  • 纯度
    >98% (HPLC)
  • 溶解度
    DMSO : ≥ 30 mg/mL 68.50 mM; H2O : < 0.1 mg/mL
  • SMILES
    CCOC(=O)N1CCC(C1)CN(Cc1ccc(cc1)Cl)Cc1ccc(s1)[N+](=O)[O-]
  • 化学全称
    ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Solt LA, et al. Nature. 2012 Mar 29;485(7396):62-8.
产品手册
关联产品
  • Fluorobexarotene

    Fluorobexarotene (compound 20) 是一种有效的 类视黄醇 X 受体 (RXR) 激动剂。Fluorobexarotene 对 RXRα 受体的 Ki 值为 12 nM,EC50 值为 43 nM。Fluorobexarotene 具有明显的 RXR 结合亲和力,比 Bexarotene 高75%。

  • BX-517

    BX-517 是一种有效的选择性 PDK1 抑制剂。

  • Acitretin

    阿维A(Ro 10-1670)是第二代系统性维A酸,已用于治疗牛皮癣。